Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
InnoCare Pharma Ltd (InnoCare) is a commercial stage biopharmaceutical company that discovers and develops drugs for the treatment of cancers and autoimmune diseases. The company’s pipeline products include orelabrutinib and tafasitamab which treats autoimmune diseases and hemato-oncology indications; ICP-B02 which targets CD20+ B-cell malignancies; ICP-248 for Non-Hodgkin Lymphoma; ICP-332 which treats atopic dermatitis; ICP-488 which targets Psoriasis; ICP-538 for autoimmune diseases; and Zurletrectinib which treats NTRK fusion-positive cancers. InnoCare leverages compound optimization platform, drug solid form research platform, formulation technology research and development and industrialization platform, biologics discover and engineering platform, CMC platform and translational medicine research platform. It operates in the US and China. InnoCare is headquartered in Changping, Beijing, China.
Headquarters
China
Address
Building 8, No. 8, Courtyard, Life Park Road, Zhongguancun Life Science Park, Beijing, 102206
Website
www.innocarepharma.com
Telephone
86 10 66609913
No of Employees
1,259
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
688428 (SHA)
Revenue (2024)
$330.5M
135.3%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
245.8%
(2024 vs 2023)
Market Cap*
$3.2B
Net Profit Margin (2024)
XYZ
162.0%
(2024 vs 2023)
* As of and is in US$
InnoCare Pharma Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | InnoCare |
| Orelabrutinib: | |
| Chronic Lymphocytic Leukemia (CLL) | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In October, the company signed an agreement with Zenas BioPharma, Inc. to grant Zenas rights to orelabrutinib for Multiple Sclerosis and non-oncology uses, and rights to a novel oral IL-17AA/AF inhibitor and a brain-penetrant TYK2 inhibitor. |
| 2025 | Regulatory Approval | In April, the company secured approval from the National Medical Products Administration for Bruton’s tyrosine kinase inhibitor orelabrutinib for use as a first-line treatment for individuals with chronic lymphocytic leukaemia and small lymphocytic lymphoma. |
| 2025 | Regulatory Approval | In February, the company received approval from the Center for Drug Evaluation of the National Medical Products Administration for a Phase III registrational clinical trial of BCL2 inhibitor ICP-248 (Mesutoclax) combined with BTK inhibitor Orelabrutinib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma. |
Competitor Comparison
| Key Parameters | InnoCare Pharma Ltd | Jiangsu Hengrui Pharmaceuticals Co Ltd | Akeso Inc | Sichuan Kelun Biotech Biopharmaceutical Co Ltd | Beijing Duality Biologics Co Ltd |
|---|---|---|---|---|---|
| Headquarters | China | China | China | China | China |
| City | Beijing | Lianyungang | Zhongshan | Chengdu | Shanghai |
| State/Province | Beijing | Jiangsu | Guangdong | Sichuan | Shanghai |
| No. of Employees | 1,259 | 20,602 | 3,761 | 1,837 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Jisong Cui | Chairman; Chief Executive Officer | Executive Board | 2019 | 62 |
| Renbin Zhao Ph.D. | Director; Senior Vice President - Medical Research and Clinical Development | Executive Board | 2019 | 57 |
| Xin Fu | Chief Financial Officer | Senior Management | 2023 | 48 |
| Kevin Gao, Ph.D. | Chief Operating Officer | Senior Management | - | - |
| Xiangyang Chen, Ph.D. | Chief Technology Officer | Senior Management | 2019 | 60 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer